Although some pioneer studies reported some potential biomarkers, such as exosomal miR-126 in CLL, exosomal IGF-1R and TGF-β1 in AML, the real clinical utilities of these biomarkers are waiting for validation in large, perspective clinical trials. The gene discussed is IGF1R; the disease is acute myeloid leukemia.